Edition:
United States

Synthetic Biologics Inc (SYN.A)

SYN.A on American Stock Exchange

0.61USD
26 May 2017
Change (% chg)

$0.01 (+2.50%)
Prev Close
$0.59
Open
$0.60
Day's High
$0.61
Day's Low
$0.58
Volume
51,203
Avg. Vol
86,252
52-wk High
$2.25
52-wk Low
$0.41

SYN.A

Chart for SYN.A

About

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $73.97
Shares Outstanding(Mil.): 121.89
Dividend: --
Yield (%): --

Financials

  SYN.A Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.20 -- --
ROI: -414.87 -8.48 -5.42
ROE: -436.30 -11.31 -4.68

BRIEF-Synthetic Biologics receives FDA breakthrough therapy designation for SYN-004

* SYN-004 (ribaxamase) receives breakthrough therapy designation from U.S. Food and Drug Administration for prevention of clostridium difficile infection

May 11 2017

BRIEF-Synthetic Biologics qtrly loss per share $0.02

* Qtrly loss per share $0.02 Source text for Eikon: Further company coverage:

May 04 2017

BRIEF-Synthetic Biologics reports preclinical data on SYN-005

* Synthetic Biologics reports preclinical data demonstrating SYN-005 provides protection from Pertussis in neonatal animal study Source text for Eikon: Further company coverage:

Apr 19 2017

BRIEF-Synthetic Biologics says confirms key features of Phase 2B/3 trial of SYN-010

* Synthetic Biologics confirms key features of pivotal Phase 2b/3 trial of SYN-010 pursuant to consultations with FDA

Jan 18 2017

Synthetic Biologics' C. difficile mid-stage study meets main goal

Synthetic Biologics Inc said its experimental treatment designed to reduce antibiotic-resistant "superbug" infections - notably life-threatening C. difficile - outperformed a placebo in a trial.

Jan 05 2017

More From Around the Web

Earnings vs. Estimates